Evidence map›Paper›PMID 24155378›Full record

ArticleJournal of virology2014

A first-in-class NAE inhibitor, MLN4924, blocks lentiviral infection in myeloid cells by disrupting neddylation-dependent Vpx-mediated SAMHD1 degradation.

Wei Wei, Haoran Guo, Xianjun Liu, Hong Zhang, Lei Qian, Kun Luo, Richard B Markham, Xiao-Fang Yu

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Association Between Neddylation and Immune Response.Frontiers in cell and developmental biology · 2022
    Review
  8. Article
  9. Article
  10. Review
  11. Roles of neddylation against viral infections.Cellular & molecular immunology · 2018
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Wei WeiSchool of Life Science, Tianjin University, Tianjin, China.
Haoran Guo
Xianjun Liu
Hong Zhang
Lei Qian
Kun Luo
Richard B Markham
Xiao-Fang Yu
Johns Hopkins University · USCollaborative Innovation Center of Chemical Science and Engineering Tianjin · CNFirst Hospital of Jilin University · CNJilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MLN4924 is a first-in-class cancer drug that inhibits the Nedd8-activating enzyme (NAE). Herein, we report that MLN4924 inhibits Vpx/Vpr-induced SAMHD1 degradation by inhibiting the neddylation of E3 ubiquitin ligase and blocks macaque simian immunodeficiency virus (SIVmac) replication in myeloid cells. SAMHD1 is required for MLN4924-mediated SIVmac inhibition. Our findings indicate the potential efficacy of inhibiting neddylation as an antiretroviral strategy and identify the readily available anticancer drug MLN4924 as a candidate agent for that purpose.

Indexed as

AnimalsCyclopentanesHumansLentivirus InfectionsMonomeric GTP-Binding ProteinsPyrimidinesSAM Domain and HD Domain-Containing Protein 1CyclopentanesMonomeric GTP-Binding ProteinspevonedistatPyrimidinesSAM Domain and HD Domain-Containing Protein 1SAMHD1 protein, human

Identifiers

PMID24155378
PMCPMC3911698
OpenAlexW2165264181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.